168 related articles for article (PubMed ID: 9170414)
1. Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline.
Iuliano R; Forastieri G; Brizzi M; Mecocci L; Mazzotta F; Ceccherini-Nelli L
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Apr; 14(5):408-14. PubMed ID: 9170414
[TBL] [Abstract][Full Text] [Related]
2. Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment.
Stellbrink HJ; Zöller B; Fenner T; Lichtenberg G; van Lunzen J; Albrecht H; Thiele HG; Greten H
AIDS; 1996 Jul; 10(8):849-57. PubMed ID: 8828742
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
[TBL] [Abstract][Full Text] [Related]
4. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
[TBL] [Abstract][Full Text] [Related]
5. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Montaner JS; DeMasi R; Hill AM
AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436
[TBL] [Abstract][Full Text] [Related]
6. Correlation between surrogate markers, viral load, and disease progression in HIV-1 infection.
Lafeuillade A; Tamalet C; Pellegrino P; de Micco P; Vignoli C; Quilichini R
J Acquir Immune Defic Syndr (1988); 1994 Oct; 7(10):1028-33. PubMed ID: 7916049
[TBL] [Abstract][Full Text] [Related]
7. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
[TBL] [Abstract][Full Text] [Related]
8. Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
Fiscus SA; Hughes MD; Lathey JL; Pi T; Jackson B; Rasheed S; Elbeik T; Reichman R; Japour A; Byington R; Scott W; Griffith BP; Katzenstein DA; Hammer SM
J Infect Dis; 1998 Mar; 177(3):625-33. PubMed ID: 9498441
[TBL] [Abstract][Full Text] [Related]
9. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
[TBL] [Abstract][Full Text] [Related]
11. Unintegrated circular HIV-1 DNA in the peripheral mononuclear cells of HIV-1-infected subjects: association with high levels of plasma HIV-1 RNA, rapid decline in CD4 count, and clinical progression to AIDS.
Panther LA; Coombs RW; Zeh JE; Collier AC; Corey L
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):303-13. PubMed ID: 9525430
[TBL] [Abstract][Full Text] [Related]
12. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
[TBL] [Abstract][Full Text] [Related]
13. Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type 1-infected persons.
Bruisten SM; Frissen PH; Van Swieten P; Harrigan PR; Kinghorn I; Larder B; Weigel HM; De Vries E; Regez RM; Henrichs JH; Koot M; Huisman JG
AIDS Res Hum Retroviruses; 1997 Mar; 13(4):327-35. PubMed ID: 9071432
[TBL] [Abstract][Full Text] [Related]
14. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
[TBL] [Abstract][Full Text] [Related]
15. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
16. Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic hiv infection during structured treatment interruptions.
Prado JG; Shintani A; Bofill M; Clotet B; Ruiz L; Martinez-Picado J
J Clin Microbiol; 2004 Apr; 42(4):1620-5. PubMed ID: 15071015
[TBL] [Abstract][Full Text] [Related]
17. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
Molina JM; Chêne G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM
J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849
[TBL] [Abstract][Full Text] [Related]
18. Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy.
Andreoni M; Parisi SG; Sarmati L; Nicastri E; Ercoli L; Mancino G; Sotgiu G; Mannazzu M; Trevenzoli M; Tridente G; Concia E; Aceti A
AIDS; 2000 Jan; 14(1):23-9. PubMed ID: 10714564
[TBL] [Abstract][Full Text] [Related]
19. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Hughes MD; Johnson VA; Hirsch MS; Bremer JW; Elbeik T; Erice A; Kuritzkes DR; Scott WA; Spector SA; Basgoz N; Fischl MA; D'Aquila RT
Ann Intern Med; 1997 Jun; 126(12):929-38. PubMed ID: 9182469
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
